Galderma Advances Restylane Volyme in Chinese Temple Hollowing
ZUG, Switzerland — September 16, 2026 Galderma announced positive topline results from a randomized study evaluating Restylane Volyme, known...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ZUG, Switzerland — September 16, 2026 Galderma announced positive topline results from a randomized study evaluating Restylane Volyme, known...
Zug, Switzerland | July 20, 2026 Galderma announced the expansion of its Alastin® regenerative skincare brand across the Japan...
ZUG, Switzerland, May 22, 2026 Galderma announced that the U.S. Food and Drug Administration (FDA) has approved the Prescription-to-Over-the-Counter...
ZUG, Switzerland, January 29, 2026 — Galderma, the global pure-play dermatology leader, has unveiled ‘Wake Up To Restylane®’, a...
